<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777827</url>
  </required_header>
  <id_info>
    <org_study_id>D6540C00002</org_study_id>
    <nct_id>NCT02777827</nct_id>
  </id_info>
  <brief_title>A Single Dose PD &amp; PK Study With Two Formulations of Abediterol in Patients With Asthma</brief_title>
  <official_title>A Randomised, Double-Blinded, Double-Dummy, Placebo-Controlled, MultiCentre-, Six-Way, Crossover Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of Abediterol Single Dose, Given by Dry Powder Inhaler (DPI) or Pressurised Metered-Dose Inhaler (pMDI), in Patients With Asthma on Inhaled Corticosteroids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacodynamics of single doses of
      abediterol given by 2 different devices in participants with asthma. Abediterol (AZD0548) is
      a potential for once daily treatment of asthma and chronic obstructive pulmonary disease
      (COPD) in fixed dose combination (FDC) with an inhaled corticosteroid (ICS) or a novel
      anti-inflammatory agent. The aim of the clinical studies is to enable further investigations
      in participants with asthma and COPD to evaluate and develop abediterol as an effective long
      acting bronchodilator with an acceptable safety profile compared to other inhaled
      bronchodilators on the market, for the treatment of asthma and COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blinded, double-dummy, placebo-controlled, multi-centre, six-way
      William's design, crossover study to assess the pharmacodynamics, pharmacokinetics, and
      safety of abediterol single dose, given by dry powder inhaler or pressurised metered-dose
      inhaler, in patients with asthma, on inhaled corticosteroids. During the screening period,
      all patients will take their own baseline inhaled corticosteroid for 2 weeks. Patients on
      long-acting β2-agonist/ inhaled corticosteroids will be switched over to the respective
      inhaled corticosteroid monocomponent. Patients will be provided salbutamol as rescue
      medication for use throughout the study. Abediterol is an investigational product in early
      stages of clinical development, therefore individual participants in the clinical studies may
      not have a clinical benefit, especially in view of alternative therapies (bronchodilators)
      being available for the treatment of asthma and COPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2016</start_date>
  <completion_date type="Actual">November 29, 2016</completion_date>
  <primary_completion_date type="Actual">November 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1).</measure>
    <time_frame>45 mins and 15 mins pre-dose, and 23.00-24.00 h post-dose on Day 1</time_frame>
    <description>Baseline for FEV1 was defined as the mean of the two measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min), prior to the morning investigational product (IP) administration on Day 1 of each treatment period. If both were missing the screening value was used instead.
Trough is defined as the mean of the FEV1 values obtained at 23 h and 24 h after the morning IP administration. If one of the values was missing, the other one was used as trough.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a ≥ 200 mL and ≥12% Increase From Baseline in Peak FEV1 on Day 1.</measure>
    <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
    <description>The percentage of patients achieving at least 200 mL and 12% increase from baseline in peak FEV1 on Day 1 of each treatment. The peak was the highest value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 at Day 1</measure>
    <time_frame>5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
    <description>The peak is the highest forced expiratory volume in one second (FEV1) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration of Abediterol (Cmax)</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Observed maximum concentration (Cmax) of Abediterol, taken directly from the individual concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (h) to Maximum Concentration of Abediterol (Tmax).</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Time to maximum concentration (Tmax) of Abediterol (h), taken directly from the individual concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant of Abediterol (λz)</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Terminal rate constant (λz) of Abediterol, estimated by log-linear least square regression of the terminal part of the concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (h) of Abediterol (t½λz)</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Terminal half-life (h), estimated as (ln2)/λz (t1/2λz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of Abediterol</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Area under the plasma concentration-curve of Abediterol from time zero to the time of last quantifiable analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Abediterol.</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Area under the Abediterol concentration-time curve from time zero extrapolated to infinity (AUC). AUC is estimated by AUClast + Clast/λz where Clast is the last observed quantifiable concentration (AUC).
PK blood samples were collected 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1 (Note that 24 h and 36 h time-points post-dose correspond to Day 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Plasma Clearance for Abediterol (CL/F).</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Apparent plasma clearance for parent drug estimated as dose divided by AUC (CL/F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution for Abediterol at Terminal Phase (Vz/F).</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Apparent volume of distribution for parent drug at terminal phase, estimated by dividing the apparent clearance (CL/F) by λz (Vz/F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) of Abediterol.</measure>
    <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
    <description>Mean residence time (h), calculated by AUMC/AUC, where AUMC is the area under the first moment-time curve (MRT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Treatment-emergent Adverse Event</measure>
    <time_frame>From screening (Day -14) up to follow-up phone call (14 days after last IP administration).</time_frame>
    <description>All treatment emergent adverse events (TEAEs), including serious AEs. An AE is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An AE was considered a TEAE if it was not present prior to the date of the first dose of IP or was present prior to the date of the first dose of IP, but increased in severity after IP administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-baseline Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Up to last treatment visit (Day 112)</time_frame>
    <description>Standard 12-lead ECG evaluations were performed prior to IP administration and 1, 4 and 24 h post IP administration at randomisation and after each IP administration. ECGs were recorded after approximately 5 minutes resting in supine position before any blood sampling and spirometry test, preferably always by the same technician for each patient.
Clinically significant abnormalities were defined as listed in the table below for QT interval, QTcB, QTcF, QRS interval, PR interval and heart rate (HR).
BL incr. = increase from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FVC at Day 1</measure>
    <time_frame>5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
    <description>The peak is the highest forced vital capacity (FVC) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a ≥ 200 mL and ≥12% Increase From Baseline in Trough FEV1.</measure>
    <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
    <description>The percentage of patients achieving at least 200 mL and 12% increase from baseline in trough forced expiratory volume in one second (FEV1). Trough was defined as the mean of the FEV1 values obtained at 23 hours and 24 hours after the morning IP administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FEV1.</measure>
    <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
    <description>The peak is the highest forced expiratory volume in one second (FEV1) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised FEV1 AUC0-24.</measure>
    <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, 6 h, 12 h, 16 h, 22 h, and 23.00-24.00 h post-dose on Day 1</time_frame>
    <description>Change from baseline in normalised FEV1 area under the concentration-curve of Abediterol from time zero to 24 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised FEV1 AUC0-12.</measure>
    <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, 6 h, and 12 h post-dose on Day 1</time_frame>
    <description>Change from baseline in normalised FEV1 area under the concentration time curve for Abediterol from time zero to 12 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised FEV1 AUC0-6.</measure>
    <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, and 6 h post dose on Day 1</time_frame>
    <description>Change from baseline in normalised FEV1 area under the concentration-curve for Abediterol from time zero to 6 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised FEV1 AUC12-24.</measure>
    <time_frame>45 mins and 15 mins predose, and 12 h, 16 h, 22 h, and 23.00-24.00 h post-dose on Day 1</time_frame>
    <description>Change from baseline in normalised FEV1 area under the concentration-curve for Abediterol from time 12 hours post-dose to 24 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak FVC.</measure>
    <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
    <description>Baseline for FVC was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.
The peak is the highest forced vital capacity (FVC) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough FVC.</measure>
    <time_frame>45 mins and 15 mins pre-dose, and 23.00-24.00 h post-dose on Day 1</time_frame>
    <description>Baseline for FVC was defined as the mean of the two measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min), prior to the morning investigational product (IP)administration on Day 1 of each treatment period. If both were missing the screening value was used instead.
Trough was defined as the mean of the FEV1 values obtained at 23 h and 24 h after the morning IP administration. If one of the values was missing, the other one was used as trough.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalised FVC AUC0-24.</measure>
    <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, 6 h, 12 h, 16 h, 22 h, and 23.00-24.00 h post-dose on Day 1</time_frame>
    <description>Change from baseline in normalised FVC area under the concentration curve for Abediterol from time zero to 24 hours post-dose.
Baseline for FVC was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FVC from Visit 2) was used instead.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Abediterol dry powder inhaler 0.156 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abediterol dry powder inhaler 2.5 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abediterol pressurised metered-dose inhaler 0.05μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abediterol pressurised metered-dose inhaler 0.156 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abediterol pressurised metered-dose inhaler 2.5μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abediterol 0.156 μg</intervention_name>
    <description>Dry powder for inhalation</description>
    <arm_group_label>Abediterol dry powder inhaler 0.156 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abediterol 2.5 μg</intervention_name>
    <description>Dry powder for inhalation</description>
    <arm_group_label>Abediterol dry powder inhaler 2.5 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abediterol 0.05 μg</intervention_name>
    <description>Pressurised metered-dose inhaler</description>
    <arm_group_label>Abediterol pressurised metered-dose inhaler 0.05μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abediterol 0.156 μg</intervention_name>
    <description>Pressurised metered-dose inhaler</description>
    <arm_group_label>Abediterol pressurised metered-dose inhaler 0.156 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abediterol 2.5 μg</intervention_name>
    <description>Pressurised metered-dose inhaler</description>
    <arm_group_label>Abediterol pressurised metered-dose inhaler 2.5μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pressurised metered-dose inhaler and dry powder for inhalation.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent before any study specific procedures.

          2. Men or non-pregnant, non-lactating women 18 to 75 years of age, inclusive.

          3. Non-smoker or ex-smoker (quit ≥6months prior to Visit 1) with a total smoking history
             of ≤10 pack years.

          4. Documented clinical diagnosis of asthma for ≥6 months before Visit 1 according to GINA
             guidelines.

          5. On stable dose of ICS or ICS/LABA FDC, for at least 1 month prior to Visit 1, at the
             doses approved in the country of enrolment.

          6. Prebronchodilator FEV1 at Visit 2 ≥40% and ≤85% of predicted (1 repetition of the test
             is allowed before screen failure).

          7. Reversibility to salbutamol (per American Thoracic Society (ATS)/European Respiratory
             Society (ERS) criteria, 2005 ie, ≥12% and ≥200 mL) at Visit 2 (1 repetition of the
             test is allowed before screen failure).

          8. Demonstrate the ability to use the study inhalation device properly.

          9. Able to perform repeated pulmonary function testing for FEV1.

         10. Able to read, speak and understand German.

         11. Patient must agree to all restrictions during the study.

        Exclusion Criteria:

          1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff at the study site).

          2. Participation in another clinical study with an IP during the last 3 months.

          3. Known or suspected hypersensitivity to the IP or excipients, including lactose (Note:
             lactose intolerance is not an exclusion).

          4. Systemic steroid use in the 6 weeks before Visit 1.

          5. Hospitalization due to asthma in the 6 months prior to Visit 1.

          6. Any active pulmonary disease other than asthma.

          7. Non-compliance with study procedures in the run in period - as judged by the
             Investigator.

          8. Treatment with biologicals such as monoclonal antibodies or chimeric biomolecules
             including omalizumab within 6 months or 5 half-lives before Visit 1 (whichever is
             longer).

          9. Treatment with any investigational drug within 30 days or 5 half-lives (whichever is
             longer) prior to Visit 1.

         10. Plasma donation within 1 month of screening or any blood donation/loss more than 500
             mL during the 3 months prior to Visit 1.

         11. Any laboratory abnormality or suspicion of any clinically relevant disease or disorder
             (on history or examination), including uncontrolled hypertension or uncontrolled
             diabetes, which, in the opinion of the Investigator, may either put the patient at
             risk because of participation in the study, or influence the results or the patient's
             ability to participate in the study, or any other safety concerns in the opinion of
             the Investigator.

         12. Known chronic hepatitis or HIV infections at the time of enrolment.

         13. Any active malignancy or treatment thereof within the 3 years prior to enrolment.

         14. Any clinically important abnormalities in rhythm, conduction, or morphology of the
             screening 12-lead ECG as judged by the Investigator on the screening ECG.

         15. Prolonged QT interval using Fridericia's correction 450 msec for males and 470 msec
             for females on the screening ECG or family history of long QT syndrome.

         16. PR (PQ) interval prolongation (&gt; 240 msec), intermittent second or third degree
             atrialventricular (AV) block or AV dissociation on the screening ECG.

         17. Implantable cardiac defibrillator and patients with sustained symptomatic ventricular
             and/or atrial tachyarrhythmia.

         18. Any contraindication against the use of sympathomimetic drugs as judged by the
             Investigator.

         19. Unstable angina pectoris or stable angina pectoris classified higher than Canadian
             Cardiovascular Society Class II, or a myocardial infarction, or stroke within 6 months
             before Visit 1.

         20. History of hospitalisation within 12 months caused by heart failure or a diagnosis of
             heart failure higher than New York Heart Association Class II.

         21. Suspected poor capability to follow instructions of the study, as judged by the
             Investigator.

         22. History of or current alcohol or drug abuse (including marijuana), as judged by the
             Investigator.

         23. Planned in-patient surgery, major dental procedure or hospitalisation during the
             study.

         24. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff,
             contract research organisation staff and/or staff at the study site).

         25. Vulnerable persons (eg, persons kept in detention). 26 Daily rescue medication
             (salbutamol) use of ≥ 12 puffs for ≥ 3 consecutive days during the run-in period.

        27. Patient who intends to use any concomitant medication not permitted by this protocol or
        not to meet the restrictions.

        28. Patient on treatment with strong CYP3A4 inhibitors such as ketoconazole or itraconazole
        or CYP3A4 inducers such as rifampin at Visit 1.

        29. Procedures for withdrawal of incorrectly enrolled patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta Beier, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biebricher Allee 34, Wiesbaden, Germany, 65187.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <results_first_submitted>June 15, 2018</results_first_submitted>
  <results_first_submitted_qc>January 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2019</results_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abediterol</keyword>
  <keyword>Dry powder inhaler</keyword>
  <keyword>Pressured metered-dose inhaler</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at four sites in Germany.
The first patient was screened 21 June 2016, the last patient visit was 29 November 2016.</recruitment_details>
      <pre_assignment_details>In total, 42 patients were screened; 30 patients were eligible to participate and were randomised.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Abediterol dry powder inhaler (DPI) 0.156 μg, followed by Abediterol pressurised metered-dose inhaler (pMDI) 0.05 μg; Placebo; Abediterol pMDI 0.156 μg; Abediterol DPI 2.5 μg; Abediterol pMDI 2.5 μg</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Abediterol pressurised metered-dose inhaler (pMDI) 0.05 μg, followed by Abediterol pMDI 0.156 μg; Abediterol dry powder inhaler (DPI) 0.156 μg; Abediterol pMDI 2.5 μg; Placebo; Abediterol DPI 2.5 μg</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Abediterol pressurised metered-dose inhaler (pMDI) 0.156 μg, followed by Abediterol pMDI 2.5 μg; Abediterol pMDI 0.05 μg; Abediterol dry powder inhaler (DPI) 2.5 μg; Abediterol DPI 0.156 μg; Placebo</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Abediterol dry powder inhaler (DPI) 2.5 μg, followed by Placebo; Abediterol pressurised metered-dose inhaler (pMDI) 2.5 μg; Abediterol DPI 0.156 μg; Abediterol pMDI 0.156 μg; Abediterol pMDI 0.05 μg</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5</title>
          <description>Abediterol pressurised metered-dose inhaler (pMDI) 2.5 μg, followed by Abediterol dry powder inhaler (DPI) 2.5 μg; Abediterol pMDI 0.156 μg; Placebo; Abediterol pMDI 0.05 μg; Abediterol DPI 0.156 μg</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6</title>
          <description>Placebo, followed by Abediterol dry powder inhaler (DPI) 0.156 μg; Abediterol DPI 2.5 μg; Abediterol pressurised metered-dose inhaler (pMDI) 0.05 μg; Abediterol pMDI 2.5 μg; Abediterol pMDI 0.156 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Periods 1 and 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Periods 2 and 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Periods 3 and 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Periods 4 and 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between Periods 5 and 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all randomised participants who received at least one dose of investigational product</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1).</title>
        <description>Baseline for FEV1 was defined as the mean of the two measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min), prior to the morning investigational product (IP) administration on Day 1 of each treatment period. If both were missing the screening value was used instead.
Trough is defined as the mean of the FEV1 values obtained at 23 h and 24 h after the morning IP administration. If one of the values was missing, the other one was used as trough.</description>
        <time_frame>45 mins and 15 mins pre-dose, and 23.00-24.00 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1).</title>
          <description>Baseline for FEV1 was defined as the mean of the two measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min), prior to the morning investigational product (IP) administration on Day 1 of each treatment period. If both were missing the screening value was used instead.
Trough is defined as the mean of the FEV1 values obtained at 23 h and 24 h after the morning IP administration. If one of the values was missing, the other one was used as trough.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" spread="0.192"/>
                    <measurement group_id="O2" value="0.400" spread="0.269"/>
                    <measurement group_id="O3" value="0.108" spread="0.212"/>
                    <measurement group_id="O4" value="0.170" spread="0.207"/>
                    <measurement group_id="O5" value="0.407" spread="0.240"/>
                    <measurement group_id="O6" value="-0.001" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least square mean</param_type>
            <param_value>0.2221</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0453</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1324</ci_lower_limit>
            <ci_upper_limit>0.3118</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.4042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0453</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3146</ci_lower_limit>
            <ci_upper_limit>0.4938</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0207</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.1056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0451</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0164</ci_lower_limit>
            <ci_upper_limit>0.1949</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.1701</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0450</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0810</ci_lower_limit>
            <ci_upper_limit>0.2592</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean</param_type>
            <param_value>0.4062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0451</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3170</ci_lower_limit>
            <ci_upper_limit>0.4955</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a ≥ 200 mL and ≥12% Increase From Baseline in Peak FEV1 on Day 1.</title>
        <description>The percentage of patients achieving at least 200 mL and 12% increase from baseline in peak FEV1 on Day 1 of each treatment. The peak was the highest value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
        <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a ≥ 200 mL and ≥12% Increase From Baseline in Peak FEV1 on Day 1.</title>
          <description>The percentage of patients achieving at least 200 mL and 12% increase from baseline in peak FEV1 on Day 1 of each treatment. The peak was the highest value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.41"/>
                    <measurement group_id="O2" value="82.76"/>
                    <measurement group_id="O3" value="56.67"/>
                    <measurement group_id="O4" value="73.33"/>
                    <measurement group_id="O5" value="90.00"/>
                    <measurement group_id="O6" value="24.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 at Day 1</title>
        <description>The peak is the highest forced expiratory volume in one second (FEV1) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
        <time_frame>5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 at Day 1</title>
          <description>The peak is the highest forced expiratory volume in one second (FEV1) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.8"/>
                    <measurement group_id="O2" value="3.3" spread="1.8"/>
                    <measurement group_id="O3" value="3.0" spread="1.9"/>
                    <measurement group_id="O4" value="3.5" spread="1.7"/>
                    <measurement group_id="O5" value="3.6" spread="2.0"/>
                    <measurement group_id="O6" value="2.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Concentration of Abediterol (Cmax)</title>
        <description>Observed maximum concentration (Cmax) of Abediterol, taken directly from the individual concentration-time curve.</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Concentration of Abediterol (Cmax)</title>
          <description>Observed maximum concentration (Cmax) of Abediterol, taken directly from the individual concentration-time curve.</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2299" spread="117.3"/>
                    <measurement group_id="O2" value="1.092" spread="47.34"/>
                    <measurement group_id="O4" value="0.2460" spread="128.7"/>
                    <measurement group_id="O5" value="1.211" spread="82.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (h) to Maximum Concentration of Abediterol (Tmax).</title>
        <description>Time to maximum concentration (Tmax) of Abediterol (h), taken directly from the individual concentration-time curve.</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Time (h) to Maximum Concentration of Abediterol (Tmax).</title>
          <description>Time to maximum concentration (Tmax) of Abediterol (h), taken directly from the individual concentration-time curve.</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" lower_limit="0.230" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.500" lower_limit="0.230" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.735" lower_limit="0.480" upper_limit="35.6"/>
                    <measurement group_id="O5" value="0.620" lower_limit="0.070" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant of Abediterol (λz)</title>
        <description>Terminal rate constant (λz) of Abediterol, estimated by log-linear least square regression of the terminal part of the concentration-time curve.</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant of Abediterol (λz)</title>
          <description>Terminal rate constant (λz) of Abediterol, estimated by log-linear least square regression of the terminal part of the concentration-time curve.</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
          <units>l/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0526" spread="0.0228"/>
                    <measurement group_id="O5" value="0.0640" spread="0.0201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (h) of Abediterol (t½λz)</title>
        <description>Terminal half-life (h), estimated as (ln2)/λz (t1/2λz).</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (h) of Abediterol (t½λz)</title>
          <description>Terminal half-life (h), estimated as (ln2)/λz (t1/2λz).</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="14.99" spread="4.827"/>
                    <measurement group_id="O5" value="11.85" spread="3.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast of Abediterol</title>
        <description>Area under the plasma concentration-curve of Abediterol from time zero to the time of last quantifiable analyte concentration.</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast of Abediterol</title>
          <description>Area under the plasma concentration-curve of Abediterol from time zero to the time of last quantifiable analyte concentration.</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
          <units>pg.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9.092" spread="53.95"/>
                    <measurement group_id="O5" value="7.674" spread="132.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Abediterol.</title>
        <description>Area under the Abediterol concentration-time curve from time zero extrapolated to infinity (AUC). AUC is estimated by AUClast + Clast/λz where Clast is the last observed quantifiable concentration (AUC).
PK blood samples were collected 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1 (Note that 24 h and 36 h time-points post-dose correspond to Day 2).</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Abediterol.</title>
          <description>Area under the Abediterol concentration-time curve from time zero extrapolated to infinity (AUC). AUC is estimated by AUClast + Clast/λz where Clast is the last observed quantifiable concentration (AUC).
PK blood samples were collected 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1 (Note that 24 h and 36 h time-points post-dose correspond to Day 2).</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter.</population>
          <units>pg.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.73" spread="43.26"/>
                    <measurement group_id="O5" value="11.08" spread="50.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Plasma Clearance for Abediterol (CL/F).</title>
        <description>Apparent plasma clearance for parent drug estimated as dose divided by AUC (CL/F).</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Plasma Clearance for Abediterol (CL/F).</title>
          <description>Apparent plasma clearance for parent drug estimated as dose divided by AUC (CL/F).</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="196.4" spread="43.26"/>
                    <measurement group_id="O5" value="225.6" spread="50.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution for Abediterol at Terminal Phase (Vz/F).</title>
        <description>Apparent volume of distribution for parent drug at terminal phase, estimated by dividing the apparent clearance (CL/F) by λz (Vz/F).</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution for Abediterol at Terminal Phase (Vz/F).</title>
          <description>Apparent volume of distribution for parent drug at terminal phase, estimated by dividing the apparent clearance (CL/F) by λz (Vz/F).</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4008" spread="37.41"/>
                    <measurement group_id="O5" value="3690" spread="49.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT) of Abediterol.</title>
        <description>Mean residence time (h), calculated by AUMC/AUC, where AUMC is the area under the first moment-time curve (MRT).</description>
        <time_frame>Pre-dose, 5, 15, 30, and 45 minutes, at 1, 2.5, 4, 6, 8, 12, 24 and 36 hours after IP administration on Day 1.</time_frame>
        <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT) of Abediterol.</title>
          <description>Mean residence time (h), calculated by AUMC/AUC, where AUMC is the area under the first moment-time curve (MRT).</description>
          <population>The PK analysis set, defined as all randomised subjects who took at least one dose of IP and had at least one evaluable relevant PK parameter</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="19.73" spread="35.48"/>
                    <measurement group_id="O5" value="15.59" spread="29.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Treatment-emergent Adverse Event</title>
        <description>All treatment emergent adverse events (TEAEs), including serious AEs. An AE is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An AE was considered a TEAE if it was not present prior to the date of the first dose of IP or was present prior to the date of the first dose of IP, but increased in severity after IP administration.</description>
        <time_frame>From screening (Day -14) up to follow-up phone call (14 days after last IP administration).</time_frame>
        <population>All randomised participants who received at least one dose of investigational product</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Treatment-emergent Adverse Event</title>
          <description>All treatment emergent adverse events (TEAEs), including serious AEs. An AE is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An AE was considered a TEAE if it was not present prior to the date of the first dose of IP or was present prior to the date of the first dose of IP, but increased in severity after IP administration.</description>
          <population>All randomised participants who received at least one dose of investigational product</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-baseline Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters</title>
        <description>Standard 12-lead ECG evaluations were performed prior to IP administration and 1, 4 and 24 h post IP administration at randomisation and after each IP administration. ECGs were recorded after approximately 5 minutes resting in supine position before any blood sampling and spirometry test, preferably always by the same technician for each patient.
Clinically significant abnormalities were defined as listed in the table below for QT interval, QTcB, QTcF, QRS interval, PR interval and heart rate (HR).
BL incr. = increase from baseline.</description>
        <time_frame>Up to last treatment visit (Day 112)</time_frame>
        <population>All randomised participants who received at least one dose of investigational product</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-baseline Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters</title>
          <description>Standard 12-lead ECG evaluations were performed prior to IP administration and 1, 4 and 24 h post IP administration at randomisation and after each IP administration. ECGs were recorded after approximately 5 minutes resting in supine position before any blood sampling and spirometry test, preferably always by the same technician for each patient.
Clinically significant abnormalities were defined as listed in the table below for QT interval, QTcB, QTcF, QRS interval, PR interval and heart rate (HR).
BL incr. = increase from baseline.</description>
          <population>All randomised participants who received at least one dose of investigational product</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QT interval &gt;450-&lt;=480msec(Day 1,1h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval BL incr. &gt;30-&lt;=60msec(Day 1,1h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval &gt;450-&lt;=480msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval BL incr. &gt;30-&lt;=60msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval BL incr. &gt;60msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval &gt;450-&lt;=480msec(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval BL incr. &gt;30-&lt;=60msec(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval &gt;450-&lt;=480msec(Day 1,1h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval &gt;450-&lt;=480msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval BL incr. &gt;30-&lt;=60msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval &gt;450-&lt;=480msec(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval BL incr. &gt;30-&lt;=60msec(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;450-&lt;=480msec(Day 1,1h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;450-&lt;=480msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval BL incr. &gt;30-&lt;=60msec(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval &gt;450-&lt;=480msec(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration &gt;=100 and incr. &gt;=25%(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval &gt;=200 and incr. &gt;=25%(Day 1,1h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval &gt;=200 and incr. &gt;=25%(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR &lt;=50 bpm and decr. &gt;=15%(Day 1,1h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR &lt;=50 bpm and decr. &gt;=15%(Day 1,4h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR &lt;=50 bpm and decr. &gt;=15%(Day 2,24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FVC at Day 1</title>
        <description>The peak is the highest forced vital capacity (FVC) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
        <time_frame>5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FVC at Day 1</title>
          <description>The peak is the highest forced vital capacity (FVC) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.8"/>
                    <measurement group_id="O2" value="2.3" spread="1.9"/>
                    <measurement group_id="O3" value="2.8" spread="2.2"/>
                    <measurement group_id="O4" value="3.2" spread="2.3"/>
                    <measurement group_id="O5" value="3.4" spread="2.2"/>
                    <measurement group_id="O6" value="1.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a ≥ 200 mL and ≥12% Increase From Baseline in Trough FEV1.</title>
        <description>The percentage of patients achieving at least 200 mL and 12% increase from baseline in trough forced expiratory volume in one second (FEV1). Trough was defined as the mean of the FEV1 values obtained at 23 hours and 24 hours after the morning IP administration.</description>
        <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a ≥ 200 mL and ≥12% Increase From Baseline in Trough FEV1.</title>
          <description>The percentage of patients achieving at least 200 mL and 12% increase from baseline in trough forced expiratory volume in one second (FEV1). Trough was defined as the mean of the FEV1 values obtained at 23 hours and 24 hours after the morning IP administration.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.03"/>
                    <measurement group_id="O2" value="72.41"/>
                    <measurement group_id="O3" value="23.33"/>
                    <measurement group_id="O4" value="26.67"/>
                    <measurement group_id="O5" value="76.67"/>
                    <measurement group_id="O6" value="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FEV1.</title>
        <description>The peak is the highest forced expiratory volume in one second (FEV1) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
        <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1.</title>
          <description>The peak is the highest forced expiratory volume in one second (FEV1) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4232" spread="0.0487"/>
                    <measurement group_id="O2" value="0.6018" spread="0.0487"/>
                    <measurement group_id="O3" value="0.2930" spread="0.0483"/>
                    <measurement group_id="O4" value="0.4280" spread="0.0482"/>
                    <measurement group_id="O5" value="0.6266" spread="0.0483"/>
                    <measurement group_id="O6" value="0.1880" spread="0.0486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised FEV1 AUC0-24.</title>
        <description>Change from baseline in normalised FEV1 area under the concentration-curve of Abediterol from time zero to 24 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
        <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, 6 h, 12 h, 16 h, 22 h, and 23.00-24.00 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised FEV1 AUC0-24.</title>
          <description>Change from baseline in normalised FEV1 area under the concentration-curve of Abediterol from time zero to 24 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2767" spread="0.0468"/>
                    <measurement group_id="O2" value="0.4813" spread="0.0468"/>
                    <measurement group_id="O3" value="0.0933" spread="0.0465"/>
                    <measurement group_id="O4" value="0.2091" spread="0.0464"/>
                    <measurement group_id="O5" value="0.4635" spread="0.0464"/>
                    <measurement group_id="O6" value="0.0124" spread="0.0472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised FEV1 AUC0-12.</title>
        <description>Change from baseline in normalised FEV1 area under the concentration time curve for Abediterol from time zero to 12 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
        <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, 6 h, and 12 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised FEV1 AUC0-12.</title>
          <description>Change from baseline in normalised FEV1 area under the concentration time curve for Abediterol from time zero to 12 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3194" spread="0.0504"/>
                    <measurement group_id="O2" value="0.5135" spread="0.0504"/>
                    <measurement group_id="O3" value="0.1575" spread="0.0500"/>
                    <measurement group_id="O4" value="0.2770" spread="0.0500"/>
                    <measurement group_id="O5" value="0.5104" spread="0.0500"/>
                    <measurement group_id="O6" value="0.0629" spread="0.0507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised FEV1 AUC0-6.</title>
        <description>Change from baseline in normalised FEV1 area under the concentration-curve for Abediterol from time zero to 6 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
        <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, and 6 h post dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised FEV1 AUC0-6.</title>
          <description>Change from baseline in normalised FEV1 area under the concentration-curve for Abediterol from time zero to 6 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3198" spread="0.0485"/>
                    <measurement group_id="O2" value="0.5044" spread="0.0485"/>
                    <measurement group_id="O3" value="0.1646" spread="0.0481"/>
                    <measurement group_id="O4" value="0.2987" spread="0.0480"/>
                    <measurement group_id="O5" value="0.5127" spread="0.0481"/>
                    <measurement group_id="O6" value="0.0654" spread="0.0484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised FEV1 AUC12-24.</title>
        <description>Change from baseline in normalised FEV1 area under the concentration-curve for Abediterol from time 12 hours post-dose to 24 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
        <time_frame>45 mins and 15 mins predose, and 12 h, 16 h, 22 h, and 23.00-24.00 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised FEV1 AUC12-24.</title>
          <description>Change from baseline in normalised FEV1 area under the concentration-curve for Abediterol from time 12 hours post-dose to 24 hours post-dose.
Baseline for FEV1 was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2339" spread="0.0479"/>
                    <measurement group_id="O2" value="0.4479" spread="0.0479"/>
                    <measurement group_id="O3" value="0.0504" spread="0.0479"/>
                    <measurement group_id="O4" value="0.1421" spread="0.0474"/>
                    <measurement group_id="O5" value="0.4169" spread="0.0474"/>
                    <measurement group_id="O6" value="-0.0346" spread="0.0487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak FVC.</title>
        <description>Baseline for FVC was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.
The peak is the highest forced vital capacity (FVC) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
        <time_frame>Predose and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h and 6 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FVC.</title>
          <description>Baseline for FVC was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FEV1 from Visit 2) was used instead.
The peak is the highest forced vital capacity (FVC) value observed during the 6 hour-period immediately after the IP dose in the morning on Day 1.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3478" spread="0.0553"/>
                    <measurement group_id="O2" value="0.4932" spread="0.0552"/>
                    <measurement group_id="O3" value="0.2867" spread="0.0550"/>
                    <measurement group_id="O4" value="0.3756" spread="0.0548"/>
                    <measurement group_id="O5" value="0.5059" spread="0.0549"/>
                    <measurement group_id="O6" value="0.2347" spread="0.0552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough FVC.</title>
        <description>Baseline for FVC was defined as the mean of the two measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min), prior to the morning investigational product (IP)administration on Day 1 of each treatment period. If both were missing the screening value was used instead.
Trough was defined as the mean of the FEV1 values obtained at 23 h and 24 h after the morning IP administration. If one of the values was missing, the other one was used as trough.</description>
        <time_frame>45 mins and 15 mins pre-dose, and 23.00-24.00 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FVC.</title>
          <description>Baseline for FVC was defined as the mean of the two measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min), prior to the morning investigational product (IP)administration on Day 1 of each treatment period. If both were missing the screening value was used instead.
Trough was defined as the mean of the FEV1 values obtained at 23 h and 24 h after the morning IP administration. If one of the values was missing, the other one was used as trough.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1702" spread="0.0523"/>
                    <measurement group_id="O2" value="0.3023" spread="0.0523"/>
                    <measurement group_id="O3" value="0.0931" spread="0.0519"/>
                    <measurement group_id="O4" value="0.1218" spread="0.0517"/>
                    <measurement group_id="O5" value="0.3134" spread="0.0518"/>
                    <measurement group_id="O6" value="0.0077" spread="0.0523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalised FVC AUC0-24.</title>
        <description>Change from baseline in normalised FVC area under the concentration curve for Abediterol from time zero to 24 hours post-dose.
Baseline for FVC was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FVC from Visit 2) was used instead.</description>
        <time_frame>45 mins and 15 mins predose, and 5 mins, 15 mins, 30 mins, 1 h, 2 h, 4 h, 6 h, 12 h, 16 h, 22 h, and 23.00-24.00 h post-dose on Day 1</time_frame>
        <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
            <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
          </group>
          <group group_id="O2">
            <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
            <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
          </group>
          <group group_id="O3">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
            <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O4">
            <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
            <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O5">
            <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
            <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalised FVC AUC0-24.</title>
          <description>Change from baseline in normalised FVC area under the concentration curve for Abediterol from time zero to 24 hours post-dose.
Baseline for FVC was defined as the mean of the 2 measured values for the corresponding variable (2 measurements 30 min apart, at -45 min and -15 min before the morning IP administration). If both values were missing, the screening value (pre-bronchodilator FVC from Visit 2) was used instead.</description>
          <population>All randomised participants who received investigational product, irrespective of protocol adherence and continued participation in the study</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2057" spread="0.0513"/>
                    <measurement group_id="O2" value="0.3646" spread="0.0512"/>
                    <measurement group_id="O3" value="0.0704" spread="0.0510"/>
                    <measurement group_id="O4" value="0.1445" spread="0.0508"/>
                    <measurement group_id="O5" value="0.3409" spread="0.0509"/>
                    <measurement group_id="O6" value="0.0309" spread="0.0517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent, throughout the treatment period and including the follow-up period (ie, 2 weeks after last IP dose). Treatment-emergent adverse events were those reported after the first dose of IP up to 30 days after last IP dose.</time_frame>
      <desc>The safety analysis set consisted of all randomised subjects who received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abediterol Dry Powder Inhaler 0.156 μg</title>
          <description>Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)</description>
        </group>
        <group group_id="E2">
          <title>Abediterol Dry Powder Inhaler 2.5 μg</title>
          <description>Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).</description>
        </group>
        <group group_id="E3">
          <title>Abediterol Pressurised Metered-dose Inhaler 0.05μg</title>
          <description>Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).</description>
        </group>
        <group group_id="E4">
          <title>Abediterol Pressurised Metered-dose Inhaler 0.156 μg</title>
          <description>Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).</description>
        </group>
        <group group_id="E5">
          <title>Abediterol Pressurised Metered-dose Inhaler 2.5μg</title>
          <description>Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of the results by the Principal Investigator (PI) will be subject to mutual agreement between the PI and the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

